SMAD3 and cancer: In cancer cell lines, studies have demonstrated that genetic or pharmacological inhibition of MYC in MCF10A basal breast cells results in increased sensitivity to TGFB-stimulated invasion and metastasis [69], and signaling via Smad3 and ERK/Sp1 mediate TGFB-induced EGFR upregulation [70].